Restricted accessResearch articleFirst published online 2023-10
Delta-9-Tetrahydrocannabinol,Cannabidiol,and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior
THC and CBD are the principal phyto-cannabinoids in the cannabis plant. The differential and possibly antagonistic effects of these compounds on specific brain and behavioral responses, and the mechanisms underlying their effects have generated extensive interest in pre-clinical and clinical neuroscience investigations.
Methods:
In this double-blind randomized placebo-controlled counterbalanced Human Laboratory Study, we examined the effects of three different dose ratios of CBD:THC (1:1, 2:1, and 3:1) on “neural noise,” an electrophysiological biomarker of psychosis known to be sensitive to cannabinoids as well as subjective and psychotomimetic effects. Healthy volunteers (n=28, 12 women) with at least one prior exposure to cannabis participated in the study.
Outcomes:
The lowest CBD (2.5 mg):THC (0.035 mg/kg) ratio (1:1) resulted in maximal attenuation of both THC-induced psychotomimetic effects (Positive and Negative Syndrome Scale [PANSS] positive: Anova Type Statistic [ATS]=7.83, pcorrected=0.015) and neural noise (ATS=8.83, pcorrected=0.009). Further addition of CBD did not reduce the subjective experience of THC-induced “high” (p>0.05 for all CBD doses).
Interpretation:
These novel results demonstrate that CBD attenuates specific THC-induced subjective and objective effects relevant to psychosis in a dose/ratio-dependent manner. Given the increasing global trend of cannabis liberalization and application for medical indications, these results assume considerable significance given the potential dose-related interactions of these key phyto-cannabinoids. Trial registration: The trial was registered in clinicaltrials.gov ID: NCT01180374.
Get full access to this article
View all access options for this article.
References
1.
ElSohlyMA, RadwanMM, GulW, et al.Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 2017; 103:1–36.
2.
BoggsDL, NguyenJD, MorgensonD, et al.Clinical and preclinical evidence for functional interactions of cannabidiol and delta(9)-tetrahydrocannabinol. Neuropsychopharmacology. 2018; 43:142–154.
3.
ColizziM, RuggeriM, BhattacharyyaS. Unraveling the intoxicating and therapeutic effects of cannabis ingredients on psychosis and cognition. Front Psychol. 2020; 11:833.
4.
D'SouzaDC, FridbergDJ, SkosnikPD, et al.Dose-related modulation of event-related potentials to novel and target stimuli by intravenous [delta]9-THC in humans. Neuropsychopharmacology. 2012; 37:1632–1646.
5.
D'SouzaDC, PerryE, MacDougallL, et al.The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004; 29:1558–1572.
6.
RanganathanM, D'SouzaD. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006; 188:425–444.
7.
RanganathanM, RadhakrishnanR, AddyPH, et al.Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79:176–183.
8.
McDonaldJ, SchleiferL, RichardsJB, et al.Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology. 2003; 28:1356.
9.
RamaekersJG, MoellerM, van RuitenbeekP, et al.Cognition and motor control as a function of Δ 9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 2006; 85:114–122.
10.
SherifM, RadhakrishnanR, D'SouzaDC, et al.Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry. 2016; 79:526–538.
11.
GaneshS, Cortes-BrionesJ, RanganathanM, et al.Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol: a mega analysis of individual participant-data from human laboratory studies. Int J Neuropsychopharmacol. 2020; 23:559–570.
12.
de Souza CrippaJA, ZuardiAW, GarridoGE, et al.Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004; 29:417–426.
13.
SkelleyJW, DeasCM, CurrenZ, et al.Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 2020; 60:253–261.
14.
AtakanZ.Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012; 2:241–254.
15.
BorgwardtSJ, AllenP, BhattacharyyaS, et al.Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry. 2008; 64:966–973.
16.
MillarSA, StoneNL, YatesAS, et al.A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018; 9:1365.
17.
Fusar-PoliP, CrippaJA, BhattacharyyaS, et al.Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009; 66:95–105.
18.
BhattacharyyaS, MorrisonPD, Fusar-PoliP, et al.Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010; 35:764–774.
19.
RussoE, GuyGW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006; 66:234–246.
20.
LongLE, MaloneDT, TaylorDA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology. 2006; 31:795–803.
21.
SkosnikPD, HajósM, Cortes-BrionesJA, et al.Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: a translational study in rats and humans. Neuropharmacology. 2018; 135:412–423.
22.
ZuardiAW, CrippaJA, HallakJE, et al.Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006; 39:421–429.
23.
BoggsDL, SurtiT, GuptaA, et al.The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. 2018; 235:1923–1932.
24.
ZuardiAW, CrippaJ, HallakJ, et al.A critical review of the antipsychotic effects of cannabidiol: 30years of a translational investigation. Curr Pharm Des. 2012; 18:5131–5140.
25.
ZuardiAW, HallakJE, DursunSM, et al.Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006; 20:683–686.
26.
LewekeF, PiomelliD, PahlischF, et al.Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 2:e94.
27.
McGuireP, RobsonP, CubalaWJ, et al.Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018; 175:225–231.
28.
WilsonR, BossongMG, Appiah-KusiE, et al.Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry. 2019; 9:1–10.
29.
Di FortiM, MarconiA, CarraE, et al.Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015; 2:233–238.
30.
Di FortiM, MorganC, DazzanP, et al.High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009; 195:488–491.
31.
Di FortiM, SallisH, AllegriF, et al.Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014; 40:1509–1517.
32.
EnglundA, MorrisonPD, NottageJ, et al.Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013; 27:19–27.
33.
HaneyM, MalcolmRJ, BabalonisS, et al.Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016; 41:1974–1982.
34.
HindochaC, FreemanTP, SchaferG, et al.Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. 2015; 25:325–334.
35.
SolowijN, BroydS, GreenwoodLM, et al.A randomised controlled trial of vaporised delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019; 269:17–35.
36.
EdwardsCR, SkosnikPD, SteinmetzAB, et al.Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations. Behav Neurosci. 2009; 123:894–904.
37.
JacobsDS, KohutSJ, JiangS, et al.Acute and chronic effects of cannabidiol on Delta(9)-tetrahydrocannabinol (delta(9)-THC)-induced disruption in stop signal task performance. Exp Clin Psychopharmacol. 2016; 24:320–330.
38.
WrightMJJr., VandewaterSA, TaffeMA.Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br J Pharmacol. 2013; 170:1365–1373.
39.
SzkudlarekHJ, DesaiSJ, RenardJ, et al.Delta-9-tetrahydrocannabinol and cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors. Neuropsychopharmacology. 2019; 44:817–825.
40.
ToddSM, ArnoldJC. Neural correlates of interactions between cannabidiol and delta(9)-tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol. 2016; 173:53–65.
41.
ToddSM, ZhouC, ClarkeDJ, et al.Interactions between cannabidiol and Delta(9)-THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol. 2017; 27:132–145.
42.
VarvelSA, WileyJL, YangR, et al.Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl). 2006; 186:226–234.
43.
Cortes-BrionesJA, CahillJD, SkosnikPD, et al.The psychosis-like effects of delta(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry. 2015; 78:805–813.
44.
LempelA, ZivJ. On the complexity of finite sequences. IEEE Trans Inform Theory. 1976; 22:75–81.
45.
LiY, TongS, LiuD, et al.Abnormal EEG complexity in patients with schizophrenia and depression. Clin Neurophysiol. 2008; 119:1232–1241.
46.
FernandezA, Lopez-IborMI, TurreroA, et al.Lempel-Ziv complexity in schizophrenia: a MEG study. Clin Neurophysiol. 2011; 122:2227–2235.
47.
FernandezA, GomezC, HorneroR, et al.Complexity and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:267–276.
48.
Cortes-BrionesJA, CahillJD, RanganathanM, et al.Testing differences in the activity of event-related potential sources: important implications for clinical researchers. Clin Neurophysiol. 2015; 126:215–218.
49.
AgurellS, HalldinM, LindgrenJE, et al.Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986; 38:21–43.
50.
OhlssonA, LindgrenJE, WahlenA, et al.Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980; 28:409–416.
51.
LindgrenJE, OhlssonA, AgurellS, et al.Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl). 1981; 74:208–212.
52.
KaySR, OplerLA, LindenmayerJP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989; 59–67.
53.
BremnerJD, KrystalJH, PutnamFW, et al.Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998; 11:125–136.
54.
HaertzenCA.Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep. 1966; 18:163–194.
55.
HaertzenCA.Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis. 1965; 141:300–307.
56.
DelormeA, MakeigS. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods. 2004; 134:9–21.
57.
D'SouzaDC, BraleyG, BlaiseR, et al.Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2008; 198:587–603.
58.
BrunnerE, DomhofS, LangerF. Nonparametric analysis of longitudinal data in factorial experiments. Wiley: New York, 2002.
59.
WickhamH, AverickM, BryanJ, et al.Welcome to the {tidyverse}. J Open Source Softw. 2019; 4:1686.
60.
NoguchiK, GelYR, BrunnerE, et al.nparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments. J Stat Softw, 2012; 50:23.
61.
BhattacharyyaS, WilsonR, Appiah-KusiE, et al.Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry. 2018; 75:1107–1117.
62.
OsborneAL, SolowijN, BabicI, et al.Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders. Brain Behav Immun. 2019; 81:574–587.
63.
OsborneAL, SolowijN, BabicI, et al.Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 95:109666.
64.
OsborneAL, SolowijN, Weston-GreenK. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017; 72:310–324.
65.
ColizziM, WeltensN, McGuireP, et al.Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. 2020; 25:3231–3240.
66.
WallMB, FreemanTP, HindochaC, et al.Individual and combined effects of Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) on striato-cortical connectivity in the human brain. bioRxiv. 2020:2020.11.20.391805.
67.
CristinoL, BisognoT, Di MarzoV. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020; 16:9–29.
68.
Di MarzoV.New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018; 17:623–639.
69.
TurnerSE, WilliamsCM, IversenL, et al.Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017; 103:61–101.
70.
MorganCJ, CurranHV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008; 192:306–307.
71.
MorganCJA, FreemanTP, SchaferGL, et al.Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010; 35:1879–1885.
72.
SchubartCD, SommerIEC, van GastelWA, et al.Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011; 130:216–221.
73.
ArkellTR, VinckenboschF, KevinRC, et al.Effect of cannabidiol and Δ9-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA. 2020; 324:2177–2186.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
